Regulatory Shifts Affecting Biotech IPOs
Biotechnology initial public offerings have historically served as a major funding mechanism for companies transitioning from early-stage research into clinical development and commercialisation. However, regulatory shifts affecting both financial markets and therapeutic product approvals are increasingly shaping how and when biotech companies pursue IPOs in the United States. In recent years, evolving disclosure requirements, regulatory … Read more